Testing extended vs. standard antibiotic infusions in children with sepsis
Part of Infections clinical trials.
This trial compares giving a long, continuous infusion versus standard short infusions of certain antibiotics (beta-lactams) to children with sepsis in intensive care. The goal is to find which method works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is 0–17 years old and in the pediatric or neonatal ICU
- Has suspected or confirmed bacterial infection and sepsis (Phoenix Sepsis Score 2 or more)
- Is being treated with a beta-lactam antibiotic such as meropenem, piperacillin/tazobactam, cefepime, or ceftriaxone
- Is not on palliative care, dialysis, ECMO, or other study drugs
- Parent or guardian provides written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a certain type of antibiotic (beta-lactam) continuously or intermittently works better for patients in the intensive care unit with pneumonia or a urinary tract infection and signs of sepsis. Sepsis is a serious response to an infection, so better antibiotic delivery could improve outcomes.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
This study tests whether giving certain antibiotics intermittently versus continuously, along with a second antibiotic, works better for hospital-acquired sepsis. It may help doctors choose the most effective way to control serious infections.
This study tests whether children can safely receive antibiotics continuously through a pump at home instead of in the hospital. The goal is to help children recover while staying with their family and avoiding prolonged hospital stays.
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
This trial tests a type of antibiotic called aminoglycosides to treat early sepsis (a serious infection). It is for adults in the hospital who are sick enough to need strong antibiotics but not in the worst stage of the illness.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.